Non-small cell lung cancer
Conditions
Interventions
RATS group:robot-assisted thoracic surgery
VATS group:video-assisted thoracic surgery
Sponsors
Sun Yat-Sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 80 years; 2. Patients with blood pressure= 40 % and DLCO >= 40 %; (3) total bilirubin = 60ml/min; 3. The first clinical diagnosis before surgery was non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other unknown types; 4. Clinical stage T1-2N0-1 (cI-II): Maximum diameter of tumor <= 5cm and short diameter of mediastinal lymph node <= 1cm in thin layer CT; 5. Performance status of ECOG 0-1; 6. All relevant examinations were completed within 28 days before the operation; 7. Patients who understand this study and have signed an approved Informed Consent.
Exclusion criteria
Exclusion criteria: 1. Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery. 2. Patients with the previous history of other malignancies; 3. Patients with secondary primary cancer when enrolled; 4. Patients diagnosed as pure ground glass opacity (GGO) before surgery; 5. Patients diagnosed as mixed GGO whose solid part <= 50% and Maximum diameter of tumor <= 2cm; 6. Patients with small cell lung cancer; 7. Patients with prior unilateral open thoracic surgical procedures; 8. Woman who is pregnant or breastfeeding; 9. Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema; 10. Patients with an active bacterial or fungal infection that is difficult to control; 11. Patients with serious psychosis; 12. Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year overall survival;3-year disease free survival;3-year overall survival;Blood loss;Conversion rate;Perioperative complication;Operative death rate;Length of stay in hospital;Pain score;R0 resection rate;Operative time;Number of mediastinal lymph node resected;Chest tube duration;Acesodyne (Grade III) dose;Total hospitalization cost; | — |
Countries
China
Contacts
Public ContactYang Haoxian
Sun Yat-Sen University Cencer Center
Outcome results
None listed